SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Nicolas Morin, Marc Morissette, Laurent Grégoire, Baltazar Gomez-Mancilla, Fabrizio Gasparini, Thérèse Di Paolo, Chronic treatment with MPEP, an mGlu5 receptor antagonist, normalizes basal ganglia glutamate neurotransmission in l-DOPA-treated parkinsonian monkeys, Neuropharmacology, 2013, 73, 216

    CrossRef

  2. 2
    Leo Metman, Christina Vaughan, Parkinson's Disease, Second Edition, 2012,

    CrossRef

  3. 3
    Spiridon Konitsiotis, Christos Tsironis, Dimitrios N. Kiortsis, Angelos Evangelou, Effects of N-methyl-d-aspartate receptor antagonism on neuroleptic-induced orofacial dyskinesias, Psychopharmacology, 2006, 185, 3, 369

    CrossRef

  4. 4
    Iracema Leroi, Deborah Collins, Laura Marsh, Non-dopaminergic treatment of cognitive impairment and dementia in Parkinson's disease: A review, Journal of the Neurological Sciences, 2006, 248, 1-2, 104

    CrossRef

  5. 5
    Francesco Bibbiani, Justin D. Oh, Animal Models of Movement Disorders, 2005,

    CrossRef

  6. 6
    Thomas N Chase, Striatal plasticity and extrapyramidal motor dysfunction, Parkinsonism & Related Disorders, 2004, 10, 5, 305

    CrossRef

  7. 7
    Michael J Marino, Ornella Valenti, P Jeffrey Conn, Glutamate Receptors and Parkinson???s Disease, Drugs & Aging, 2003, 20, 5, 377

    CrossRef

  8. 8
    Thomas N. Chase, Francesco Bibbiani, Justin D. Oh, Striatal glutamatergic mechanisms and extrapyramidal movement disorders, Neurotoxicity Research, 2003, 5, 1-2, 139

    CrossRef

  9. 9
    Serge Przedborski, Vladimir Kosti_, Nir Giladi, David Eidelberg, Dopamine Receptors and Transporters, 2003,

    CrossRef

  10. 10
    Frédéric Calon, Marc Morissette, Othman Ghribi, Martin Goulet, Richard Grondin, Pierre J Blanchet, Paul J Bédard, Thérèse DiPaolo, Alteration of glutamate receptors in the striatum of dyskinetic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated monkeys following dopamine agonist treatment, Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2002, 26, 1, 127

    CrossRef

  11. 11
    G.F. Wooten, Anatomy and function of dopamine receptors: understanding the pathophysiology of fluctuations in Parkinson's disease, Parkinsonism & Related Disorders, 2001, 8, 2, 79

    CrossRef

  12. 12
    Concepció Marin, Anna Jimenez, Mercè Bonastre, Thomas N. Chase, Eduardo Tolosa, Non-NMDA receptor-mediated mechanisms are involved in levodopa-induced motor response alterations in parkinsonian rats, Synapse, 2000, 36, 4
  13. 13
    Leo Verhagen Metman, Spiridon Konitsiotis, Thomas N. Chase, Pathophysiology of motor response complications in Parkinson's disease: Hypotheses on the why, where, and what, Movement Disorders, 2000, 15, 1
  14. 14
    Thomas N. Chase, Justin D. Oh, Striatal dopamine- and glutamate-mediated dysregulation in experimental parkinsonism, Trends in Neurosciences, 2000, 23, S86

    CrossRef

  15. 15
    Hasmet A. Hanaḡasi, Gülüstü Kaptanoǧlu, Hüseyin A. Sahin, Murat Emre, The use of NMDA antagonist memantine in drug-resistant dyskinesias resulting from l-dopa, Movement Disorders, 2000, 15, 5
  16. 16
    Justin D Oh, Christina L Vaughan, Thomas N Chase, Effect of dopamine denervation and dopamine agonist administration on serine phosphorylation of striatal nmda receptor subunits, Brain Research, 1999, 821, 2, 433

    CrossRef

  17. 17
    Joseph Jankovic, Eugene Lai, Lea Ben-Arie, Joachim K Krauss, Robert Grossman, Levodopa-induced dyskinesias treated by pallidotomy, Journal of the Neurological Sciences, 1999, 167, 1, 62

    CrossRef

  18. 18
    Leo Verhagen Metman, Pierre J. Blanchet, Pepÿn van den Munckhof, Paolo Del Dotto, Remco Natté, Thomas N. Chase, A trial of dextromethorphan in parkinsonian patients with motor response complications, Movement Disorders, 1998, 13, 3
  19. 19
    Pierre J. Blanchet, Spyridon Konitsiotis, Thomas N. Chase, Amantadine reduces levodopa-induced dyskinesias in parkinsonian monkeys, Movement Disorders, 1998, 13, 5
  20. 20
    L. Verhagen Metman, P. Del Dotto, P. J. Blanchet, P. van den Munckhof, T. N. Chase, Blockade of glutamatergic transmission as treatment for dyskinesias and motor fluctuations in Parkinson's disease, Amino Acids, 1998, 14, 1-3, 75

    CrossRef

  21. 21
    Justin D Oh, David Russell, Christina L Vaughan, Thomas N Chase, Enhanced tyrosine phosphorylation of striatal NMDA receptor subunits: effect of dopaminergic denervation and l-DOPA administration, Brain Research, 1998, 813, 1, 150

    CrossRef

  22. 22
    M.Maral Mouradian, Thomas N. Chase, Gene Therapy for Parkinson's Disease: An Approach to the Prevention or Palliation of Levodopa-Associated Motor Complications, Experimental Neurology, 1997, 144, 1, 51

    CrossRef

  23. 23
    Pierre J. Blanchet, Stella M. Papa, Leo Verhagen Metman, M.Maral Mouradian, Thomas N. Chase, Modulation of levodopa-induced motor response complications by NMDA antagonists in Parkinson's disease, Neuroscience & Biobehavioral Reviews, 1997, 21, 4, 447

    CrossRef

  24. 24
    Justin D Oh, Paolo Del Dotto, Thomas N. Chase, Protein kinase A inhibitor attenuates levodopa-induced motor response alterations in the hemi-parkinsonian rat, Neuroscience Letters, 1997, 228, 1, 5

    CrossRef